Request Free Sample ×

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor

MRSA Drugs Companies

ID: MRFR/Pharma/1570-CR
128 Pages
Satyendra Maurya
Last Updated: February 16, 2025
Methicillin-resistant Staphylococcus aureus (MRSA) is a type of bacteria that has become resistant to many commonly used antibiotics. Companies in the pharmaceutical and biotechnology industries play a critical role in developing drugs and treatment options to combat MRSA infections.
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

MRSA Drugs Market
Market Size
Forecast Period2025 - 2035
CAGR (2025 - 2035)4.1%
2024 Market Size$ 3.45 Billion
2025 Market Size$ 3.59 Billion
2035 Market Size$ 5.37 Billion
Key Players
Pfizer
Merck & Co
Johnson & Johnson
Novartis
Bristol-Myers Squibb
AstraZeneca
Opportunities
  • Increased Healthcare Expenditure
  • Advancements in Antibiotic Research
  • Rising Awareness of MRSA Infections

Top Industry Leaders in the MRSA Drugs Market

<a href=MRSA Drugs Key Companies" width="600" height="300">Disclaimer: List of key companies in no particular orderLatest MRSA Companies Update
  • June 2023: Drugmaker Sanofi called the rival pharmaceutical company's court filing "improper" in a battle over the retail market for the EpiPen auto-injector device, and on Wednesday, the U.S. judge granted Sanofi's request to limit Mylan's attempt to recoup litigation costs in an antitrust complaint. After successfully fending Sanofi's accusations, Mylan—now a part of the Pennsylvania-based healthcare corporation Viatris—requests reimbursement for litigation expenditures. The disagreement will now be heard in federal court, according to the two companies, which claimed they could not agree over costs.
Get In-Depth Insights on Key MRSA Drugs Companies
  • Oct 2023: At its location in Settimo, Italy, Olon Biotech, a branch of the Italian API manufacturer Olon, has opened a new facility for the large-scale synthesis of proteins from alternative sources. Olon estimated that the new plant would cost €70 million to build. Since alternative proteins are employed in many non-animal, non-vegetable product categories, such as food and drinks, they are considered extremely sustainable and do not affect the environment. The company has announced a significant investment plan to modernize and expand its facilities, which create active substances using cutting-edge, environmentally friendly biotechnological techniques.
List of MRSA Key companies in the market
  • Merck KGaA (UK)
  • Olon (Italy)
  • Allergan (Dublin, Ireland)
  • Baxter (US)
  • Theravance Biopharma (Theravance Biopharma)
  • Pfizer (US)
  • Mylan NV (US)
  • Novartis (Switzerland)